@article{1f3b09949678400a8eac0da690c8a869,
title = "The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization",
abstract = "Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.",
author = "Jing Zou and Xuping Xie and Fontes-Garfias, {Camila R.} and Swanson, {Kena A.} and Isis Kanevsky and Kristin Tompkins and Mark Cutler and David Cooper and Dormitzer, {Philip R.} and Shi, {Pei Yong}",
note = "Funding Information: We thank colleagues at Pfizer, BioNTech, and UTMB for helpful discussions and support during the study. We thank the Pfizer-BioNTech clinical trial C4591001 participants, from whom the post-immunization human sera were obtained, and the staff of the New Iberia Research Center, who provided the rhesus macaque post-immunization sera. We thank the many colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine candidate. P.-Y.S. was supported by NIH grants AI134907 and UL1TR001439, and awards from the Sealy & Smith Foundation, Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
month = dec,
doi = "10.1038/s41541-021-00313-8",
language = "English (US)",
volume = "6",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",
}